Published in Oncotarget on August 16, 2016
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
T cell exhaustion. Nat Immunol (2011) 11.08
Getting to the root of miRNA-mediated gene silencing. Cell (2008) 7.17
Redefining chronic viral infection. Cell (2009) 6.30
Tumour necrosis factor and cancer. Nat Rev Cancer (2009) 6.27
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 4.79
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A (2010) 3.12
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 2.50
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2011) 2.26
Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother (2006) 2.20
The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. Curr Opin Immunol (2009) 1.71
Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett (2013) 1.54
miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. Biochem Biophys Res Commun (2010) 1.53
MicroRNAs in the search for understanding human diseases. BioDrugs (2007) 1.47
miR-28-5p promotes chromosomal instability in VHL-associated cancers by inhibiting Mad2 translation. Cancer Res (2014) 1.45
Differential expression of miRNAs in esophageal cancer tissue. Oncol Lett (2013) 1.38
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun (2015) 1.36
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov (2016) 1.34
T-cell exhaustion in the tumor microenvironment. Cell Death Dis (2015) 1.32
Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. Anal Biochem (2011) 1.25
TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology (2013) 1.22
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract (2014) 1.13
Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma. Transl Oncol (2013) 1.08
PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother (2014) 1.08
Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med (2014) 1.06
Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis. Oncogene (2012) 1.06
Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol (2013) 1.03
PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst (2015) 1.02
Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J Immunol (2013) 1.02
The role of microRNA in rheumatoid arthritis and other autoimmune diseases. Clin Immunol (2010) 1.01
MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas. Proc Natl Acad Sci U S A (2014) 0.96
New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Ther Adv Med Oncol (2013) 0.92
From T cell "exhaustion" to anti-cancer immunity. Biochim Biophys Acta (2015) 0.88
PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J (2015) 0.87
T cell exhaustion and Interleukin 2 downregulation. Cytokine (2014) 0.85
microRNA-4717 differentially interacts with its polymorphic target in the PD1 3' untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases. Oncotarget (2015) 0.82
Glial cells suppress postencephalitic CD8+ T lymphocytes through PD-L1. Glia (2014) 0.82
Depletion of the programmed death-1 receptor completely reverses established clonal anergy in CD4(+) T lymphocytes via an interleukin-2-dependent mechanism. Cell Immunol (2009) 0.79
Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines. J Immunother (2016) 0.77